Purpose: To determine the effect of Voglibose add-on therapy on daily glycemic excursions (using FreeStyle ® Libre Pro™, a Flash glucose monitoring system) in Indian patients with type 2 diabetes (T2DM) receiving a stable dose of metformin (Met) or metformin+sulfonylurea (Met+SU). Patients and Methods: T2DM patients with glycosylated hemoglobin (HbA1c) >7.0% and at least two postprandial excursions > 140 mg/dL (within 2 hours of meal) during the screening phase (visit 1/day-14±2), were enrolled in this prospective, multi-centre interventional study. The patients were randomized at visit 2 (Day 0±2) to receive Voglibose 0.2 mg or 0.3 mg tablets (BID/TID) as add-on therapy to Met and Met+SU. All